Peptide

Adipotide

Also known as

FTPP · Fat-Targeted Proapoptotic Peptide · FTTP (common misspelling of FTPP) · Prohibitin-TP01 · Prohibitin-targeting peptide 1 · TP01 · CKGGRAKDC-GG-D(KLAKLAK)2 · Arrowhead Adipotide / Ablaris adipotide (historical development)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Experimental fat-loss compound	Adipotide, also called FTPP or Prohibitin-TP01, targets blood vessels feeding white fat. It is a peptide-based molecule with a cell-killing component.
Systemic exposure	Injection near a bulge does not establish selective fat loss there. The accounts do not establish oral, nasal or topical equivalents.

Notes

FTPP and Prohibitin-TP01 are other names for Adipotide. A tissue-homing sequence carries a cell-killing component to white-fat blood vessels. Animal research describes loss of that supporting circulation. This differs from GLP-1 appetite signaling or releasing stored fat for fuel. Barnhart et al. (2011) — white-fat targeting in obese monkeys (Animal context · Accessed 2026-09-30)

A targeted molecule does not mean targeted injection-site fat loss. The existing discussion describes systemic exposure, not choosing which bulge disappears. SubQ means injection beneath the skin. Oral, nasal and topical equivalents are not established in this record, and Adipotide is one molecule, not a fixed-ratio blend.

Source context — Barnhart et al. (2011) — white-fat targeting in obese monkeys: Abstract and figure captions inspected; PMC full-text body blocked by browser challenge. Animal endpoints do not establish human dosing, permanent fat loss, human PK or universal reversibility. Detailed legacy urine/electrolyte and MRI percentage claims not freshly verified from full text.

What people notice

Definition and weight	One three-week account at 1 mg/day reported about 5 lb lost, a smaller waist and more visible veins. Another log's early loss returned with rehydration; that author also used tirzepatide.
Appetite and mixed results	An AOD-9604 co-user described less hunger. Other accounts found little fat-loss benefit despite uncomfortable injections.

Notes

A smaller waist, more visible veins and less facial fat. A three-week Reddit account claimed about 5 lb lost at 1 mg/day, unchanged strength and improved definition after an earlier diet-and-training loss. The author also reported increased urination. Appearance and scale reports do not measure destroyed fat cells. AdAffectionate6360 — My thoughts on Adipotide (Personal report · Accessed 2026-09-30)

Another log's early loss returned with rehydration. ChrisBGood used tirzepatide; a cut began on day 20 after little progress. The final lower weight cannot isolate Adipotide. Burning/itching lasted minutes, sometimes with day-long irritation. ChrisBGood — Adipotide Experiment, completed 28-day self-log (Personal report · Accessed 2026-09-30)

Appetite relief appears in some accounts, without a reliable response pattern. TPTPB41 needed reminders to eat during AOD-9604 co-use. That does not isolate Adipotide's effect. TPTPB41 — Adipotide and AOD 9604 experience and updates (Personal report · Accessed 2026-09-30)

Tender lumps and disappointing fat loss appear beyond Reddit. Imip007's lumps lasted about a week; an IM switch followed. Month-long results disappointed, with clenbuterol/T3 added in week three. This confounds attribution. Imip007 — Adipotide (ftpp), MESO-Rx (Personal report · Accessed 2026-09-30)

Source context — AdAffectionate6360 — My thoughts on Adipotide: Optimistic uncontrolled testimony with no opened laboratory results, no verified fat measurement and no route in opening dose statement. Claims about being a golden ticket, hydration protection, permanent fat-cell removal and human trial lesions are not adopted as established facts. Concern about facial aging is a reply's concern, not an observed adverse outcome.

Source context — ChrisBGood — Adipotide Experiment, completed 28-day self-log: Tirzepatide co-use, illness, water/bowel shifts and late dietary cut confound outcome; body-fat estimates are not confirmed imaging. Inconsistent mg/kg, mg and syringe-unit equivalences make OP dose unusable. Reply's 5 mg/day is self-report; planned 10 mg/day is not completed use and is not adopted.

Source context — TPTPB41 — Adipotide and AOD 9604 experience and updates: Self-report with AOD-9604 300 mcg/day, keto and OMAD; no independently checked fat imaging or kidney lab panel. Opening says shots but not SubQ. A later update's June 2025 year conflicts with displayed 2024 comment context; retain relative follow-up only. Replies are distinct users, not additional OP outcomes.

Source context — Imip007 — Adipotide (ftpp), MESO-Rx: Only page 1 inspected, not pages 2–3. First two weeks' once-daily pattern is inferred from morning shots and later daily statement; later 3 mg/day is explicit. Product identity and outcome not verified; route change and clen/T3 confound results. Copied research/cause-of-termination speculation in replies is not evidence. Do not reproduce mix or syringe recipe.

Doses people talk about

Fixed-amount charts	250–1,000 mcg beneath the skin daily appears in circulated charts. Calculator entries do not verify actual use or outcomes.
Weight-based charts	0.01 mg/kg daily is a separate chart convention, not a demonstrated safe limit or a conversion of every fixed-dose chart.
Personal accounts	1 mg/day appears in reports, including one with AOD-9604 300 mcg/day. That co-use post did not specify the injection route.
Higher reported exposure	Separate accounts describe 1, then 2, then 3 mg/day with a route change, or 5 mg/day for 20 days. These reports do not establish greater benefit or a safe ceiling.

Notes

250–1,000 mcg SubQ daily in circulated charts. That fixed-amount band remains in the original community record. A commercial calculator site reports 250 mcg as its median entry and 500 mcg as its most frequent entry; calculator inputs are not verified administrations or outcomes. World Peptide Association — Adipotide community calculator data (Community guide · Accessed 2026-09-30)

0.01 mg/kg daily is a separate weight-chart claim. Older charts list roughly 455–680 mcg for 100–150 lb, 685–905 mcg for 151–200 lb and 910–1,150 mcg for 201–250 lb. Their claimed ceiling is not a demonstrated safe limit. The repeated 4.53 mcg/lb figure is rounded; it does not equal 1 mg at 200 lb.

1 mg/day appears in personal accounts, sometimes with AOD-9604 300 mcg/day. TPTPB41's two daily injections were not a standardized blend; the post does not specify SubQ. TPTPB41 — Adipotide and AOD 9604 experience and updates (Personal report · Accessed 2026-09-30)

Higher daily amounts also appear, without establishing greater benefit. MESO-Rx: 1 mg, then 2 mg, then 3 mg/day, with SubQ changing to IM. A separate Reddit reply claimed 5 mg/day for 20 days. Neither validates escalation. Imip007 — Adipotide (ftpp), MESO-Rx (Personal report · Accessed 2026-09-30) · ChrisBGood — Adipotide Experiment, completed 28-day self-log (Personal report · Accessed 2026-09-30)

Source context — World Peptide Association — Adipotide community calculator data: Calculator sessions are inputs, not verified people, injections, safety or benefits; repeated sessions may belong to one user. Vendor-comparison links show commercial adjacency. Its unsupported 2-hour clearance/no-carryover claim and pilot-human toxicity assertion are not adopted. No mixing volumes or purchase instructions reproduced.

Half-life, onset & duration

Felt onset	Appetite impressions and injection burning can be immediate. Visible changes were reported over weeks, while another account saw no first-week fat-percentage reduction.
Felt duration	No dependable single-dose benefit window is documented. One co-user reported continued weight loss for three weeks after stopping; that does not measure peptide activity.
Half-life	About 2–4 hours is circulated lore. The human half-life remains unresolved; a tracking app's two-hour model is not a measurement.

Notes

Immediate sensations can be appetite impressions or injection discomfort. One co-use account reported immediate appetite quieting; another reported immediate burning/itching. Neither establishes fat-loss onset. TPTPB41 — Adipotide and AOD 9604 experience and updates (Personal report · Accessed 2026-09-30) · ChrisBGood — Adipotide Experiment, completed 28-day self-log (Personal report · Accessed 2026-09-30)

Visible change is reported over weeks, or barely at all. A three-week account reported better definition; another reported no first-week fat-percentage reduction. A consistent timetable is unknown. AdAffectionate6360 — My thoughts on Adipotide (Personal report · Accessed 2026-09-30) · ChrisBGood — Adipotide Experiment, completed 28-day self-log (Personal report · Accessed 2026-09-30)

No dependable single-dose benefit window is documented. The appetite observation ran from 6 AM dosing to an 11:30 AM update; an update time is not when hunger returned. TPTPB41 — Adipotide and AOD 9604 experience and updates (Personal report · Accessed 2026-09-30)

One account reported continued loss for three weeks after stopping. TPTPB41 reported 1 lb/week, then a two-month stall. Co-use/diet confound this follow-up; it does not measure peptide activity. TPTPB41 — Adipotide and AOD 9604 experience and updates (Personal report · Accessed 2026-09-30)

About 2–4 hours is circulated lore; human half-life remains unresolved. The original secondary/community notes retain that range. BioHack Track uses 2 hours for its decay model while explicitly saying human half-life is poorly characterized. An app's estimated active-level curve is not a measured human pharmacokinetic result. BioHack Track — Adipotide (FTPP) compound reference (Community guide · Accessed 2026-09-30)

Source context — BioHack Track — Adipotide (FTPP) compound reference: Commercial app reference, not original PK research. No specific human measurement supports the model. Do not convert its calculated active levels into a proven clearance/safety window. Reconstitution instructions were not adopted.

Cycles people discuss

Month-long courses	28–30 days recur in logs and four-week charts. Safe repeat intervals and back-to-back courses are not established.
Short on/off suggestion	One guide displayed alongside supplier advertising proposes one week on, one off, then another on. It is the author's hypothetical schedule, not completed use or tested protection.

Notes

28–30 days recur in logs, but repeat-course safety is unknown. Four-week chart templates borrow from research designs. A safe interval for repeated or back-to-back blocks is not established; animal recovery observation is not a human washout rule.

Shorter on/off suggestions are opinion, not tested protection. A bodybuilding guide displayed alongside supplier advertising proposes 0.5 mg SubQ daily for one week, one week off, then another week on. It describes what the author would do, not completed use; breaks, hydration and supplements do not validate safety. 01dragonslayer — Adipotide: dangerous fat-burner or miracle drug? (Community opinion · Accessed 2026-09-30)

Source context — 01dragonslayer — Adipotide: dangerous fat-burner or miracle drug?: Hypothetical opinion, not a completed personal course. Commercial contact in post and supplier advertising around it; efficacy, no-cardiovascular-side-effect and ancillary-protection assertions are unsupported. Schedule is preserved as discussion only, without supplement instructions, contact or purchase details.

Stacks

AOD-9604	One account used Adipotide 1 mg/day with AOD-9604 300 mcg/day, alongside keto and one meal a day. Its weight and appetite reports cannot isolate Adipotide.
Other weight-loss drugs	A completed log included tirzepatide; another added clenbuterol and T3 in week three. These were separate histories, with different diets and outcomes.

Notes

An enthusiastic co-use log reported 12 lb lost in two weeks. Keto and one meal a day continued. Hunger/thirst partly returned; sleep/energy reportedly improved. The author reported no kidney issues and no second round; neither verifies safety. TPTPB41 — Adipotide and AOD 9604 experience and updates (Personal report · Accessed 2026-09-30)

Watch for

Kidney injury	Animal research found kidney-tubule injury. Feeling well, drinking water or stopping later does not establish protection or guaranteed recovery in people.
Injection discomfort	Reports include burning, itching, day-long irritation and tender lumps lasting about a week.
Units and product contents	One self-log mixed up syringe units, mg and mg/kg, making its dose unusable. Vial labels do not verify contents, and long-term repeated-use safety is uncharacterized.

Notes

Kidney injury is part of the research signal. Animal captions show tubular injury and creatinine changes not mirrored by BUN. Recovery in monkeys does not guarantee recovery in humans. Barnhart et al. (2011) — white-fat targeting in obese monkeys (Animal context · Accessed 2026-09-30)

Feeling well or drinking water does not show that the kidneys are unharmed. Eroids posters dispute universal recovery after stopping. One participant's earlier injury concerned another medication. Neither that story nor copied monkey summaries demonstrates protection from Adipotide. Caeser — Adipotide (FTPP), Eroids kidney-risk discussion (Community discussion · Accessed 2026-09-30)

Syringe units, mg and mg/kg are not interchangeable. The completed self-log inconsistently equates these units; its dose cannot be recovered reliably. Animal scaling does not establish a safe human amount. ChrisBGood — Adipotide Experiment, completed 28-day self-log (Personal report · Accessed 2026-09-30)

Unverified products and combined drugs complicate every claim. Vial labels do not establish sequence, purity or fill accuracy. Lack of nausea does not exclude renal injury, and there is no characterized long-term safety record for repeated use or special populations here. ClinicalTrials.gov — NCT01262664, Prohibitin Targeting Peptide 1 (Official context · Accessed 2026-09-30)

Source context — Caeser — Adipotide (FTPP), Eroids kidney-risk discussion: Secondhand peptide-risk talk and copied unnamed monkey summaries, not measured Adipotide outcomes. Johnny Bravo's past acute kidney injury concerned another medication and is not treated as an Adipotide adverse case. Neither hydration protection nor universal reversibility is established. Embedded interview video was not inspected.

Source context — ClinicalTrials.gov — NCT01262664, Prohibitin Targeting Peptide 1: HTML page gave only application shell; web API open errored, but Python HTTPS read succeeded. Registry is a trial design/status record, not a results paper. Terminated per PI request does not identify toxicity as reason; no measured half-life, safe dose, completed MTD or public efficacy results inferred.

Full notes

Adipotide is an experimental peptide discussed for fat loss by targeting white-fat blood vessels. Reports range from better definition to little benefit and uncomfortable injections. Kidney injury is the central concern; animal headlines do not establish a dependable human result.

What Adipotide is

FTPP and Prohibitin-TP01 are other names for Adipotide. A tissue-homing sequence carries a cell-killing component to white-fat blood vessels. Animal research describes loss of that supporting circulation. This differs from GLP-1 appetite signaling or releasing stored fat for fuel. Animal context Community
A targeted molecule does not mean targeted injection-site fat loss. The existing discussion describes systemic exposure, not choosing which bulge disappears. SubQ means injection beneath the skin. Oral, nasal and topical equivalents are not established in this record, and Adipotide is one molecule, not a fixed-ratio blend. Community

Benefits people seek and report

A smaller waist, more visible veins and less facial fat. A three-week Reddit account claimed about 5 lb lost at 1 mg/day, unchanged strength and improved definition after an earlier diet-and-training loss. The author also reported increased urination. Appearance and scale reports do not measure destroyed fat cells. Personal report
Appetite relief appears in some accounts, without a reliable response pattern. TPTPB41 needed reminders to eat during AOD-9604 co-use. That does not isolate Adipotide's effect. Personal report

Doses people discuss

These are reported amounts and circulated charts, not an established human dose or a suggested progression. Daily totals and weight-based figures are separate claims.

250–1,000 mcg SubQ daily in circulated charts. That fixed-amount band remains in the original community record. A commercial calculator site reports 250 mcg as its median entry and 500 mcg as its most frequent entry; calculator inputs are not verified administrations or outcomes. Community Community guide
0.01 mg/kg daily is a separate weight-chart claim. Older charts list roughly 455–680 mcg for 100–150 lb, 685–905 mcg for 151–200 lb and 910–1,150 mcg for 201–250 lb. Their claimed ceiling is not a demonstrated safe limit. The repeated 4.53 mcg/lb figure is rounded; it does not equal 1 mg at 200 lb. Community
1 mg/day appears in personal accounts, sometimes with AOD-9604 300 mcg/day. TPTPB41's two daily injections were not a standardized blend; the post does not specify SubQ. Personal report
Higher daily amounts also appear, without establishing greater benefit. MESO-Rx: 1 mg, then 2 mg, then 3 mg/day, with SubQ changing to IM. A separate Reddit reply claimed 5 mg/day for 20 days. Neither validates escalation. Personal report Personal report

Half-life

About 2–4 hours is circulated lore; human half-life remains unresolved. The original secondary/community notes retain that range. BioHack Track uses 2 hours for its decay model while explicitly saying human half-life is poorly characterized. An app's estimated active-level curve is not a measured human pharmacokinetic result. Community Community guide

Onset: when people notice something

Immediate sensations can be appetite impressions or injection discomfort. One co-use account reported immediate appetite quieting; another reported immediate burning/itching. Neither establishes fat-loss onset. Personal report Personal report
Visible change is reported over weeks, or barely at all. A three-week account reported better definition; another reported no first-week fat-percentage reduction. A consistent timetable is unknown. Personal report Personal report

Duration: how long reported effects last

No dependable single-dose benefit window is documented. The appetite observation ran from 6 AM dosing to an 11:30 AM update; an update time is not when hunger returned. Personal report
One account reported continued loss for three weeks after stopping. TPTPB41 reported 1 lb/week, then a two-month stall. Co-use/diet confound this follow-up; it does not measure peptide activity. Personal report

Cycles and breaks

28–30 days recur in logs, but repeat-course safety is unknown. Four-week chart templates borrow from research designs. A safe interval for repeated or back-to-back blocks is not established; animal recovery observation is not a human washout rule. Community
Shorter on/off suggestions are opinion, not tested protection. A bodybuilding guide displayed alongside supplier advertising proposes 0.5 mg SubQ daily for one week, one week off, then another week on. It describes what the author would do, not completed use; breaks, hydration and supplements do not validate safety. Anabolic Steroid Forums

Good to know

Kidney injury is part of the research signal. Animal captions show tubular injury and creatinine changes not mirrored by BUN. Recovery in monkeys does not guarantee recovery in humans. Animal context
Feeling well or drinking water does not show that the kidneys are unharmed. Eroids posters dispute universal recovery after stopping. One participant's earlier injury concerned another medication. Neither that story nor copied monkey summaries demonstrates protection from Adipotide. Eroids bodybuilding forum
Syringe units, mg and mg/kg are not interchangeable. The completed self-log inconsistently equates these units; its dose cannot be recovered reliably. Animal scaling does not establish a safe human amount. Personal report Community
Unverified products and combined drugs complicate every claim. Vial labels do not establish sequence, purity or fill accuracy. Lack of nausea does not exclude renal injury, and there is no characterized long-term safety record for repeated use or special populations here. Community Official context

From community experience

An enthusiastic co-use log reported 12 lb lost in two weeks. Keto and one meal a day continued. Hunger/thirst partly returned; sleep/energy reportedly improved. The author reported no kidney issues and no second round; neither verifies safety. Personal report
Another log's early loss returned with rehydration. ChrisBGood used tirzepatide; a cut began on day 20 after little progress. The final lower weight cannot isolate Adipotide. Burning/itching lasted minutes, sometimes with day-long irritation. Personal report
Tender lumps and disappointing fat loss appear beyond Reddit. Imip007's lumps lasted about a week; an IM switch followed. Month-long results disappointed, with clenbuterol/T3 added in week three. This confounds attribution. Personal report
A slimmer face can be welcome or unwanted. The positive poster welcomed jaw change; a reply worried about cheek/temple loss and aging appearance. Neither establishes selectable fat loss; no unwanted facial-loss outcome was reported there. Personal report
Bostin Loyd's reported 5 mg/day use remains cautionary lore. The original narrative links it to severe kidney disease amid extensive drug co-use; Eroids repeats the warning. Sole causation and smaller-amount safety cannot be inferred. Community Eroids bodybuilding forum
Comparison talk is broader than an established stack. Older discussions compare AOD-9604, Fragment 176-191, GLP-1 drugs, Tesamorelin, 5-Amino-1MQ and BAM15. Diet, training, steps and sleep also accompany cut reports. Co-mention, sequential use or adding other research agents does not validate a combination. Community

Separately labeled research context

The familiar 10.6% weight-loss figure is from obese rhesus monkeys. The study used 0.43 mg/kg SubQ daily for 28 days, then 28 days of recovery observation. Imaging confirmed less white fat. These are animal endpoints, not human expectations. Animal context
The human registry supplies a design, not results. NCT01262664 lists 0.03 mg/kg beneath the skin daily for 28 days in an obese metastatic-prostate-cancer population. It is terminated per the investigator's request, with no posted results; it does not establish a measured human half-life or explain termination as proven toxicity. Official context